Single-Cell Cardiovascular Mapping for Tailored Cardiac Care

Abstract

Single-cell cardiovascular mapping represents a transformative advancement in the understanding and management of cardiac diseases. By leveraging high-resolution technologies to dissect complex cardiac cellular heterogeneity, this approach enables personalized insights into pathophysiology, risk stratification, and targeted therapies. This review provides an in-depth analysis of the epidemiological relevance, mechanisms, and clinical translation of single-cell mapping in cardiovascular care, underscoring its potential to revolutionize diagnostics, prognostication, and tailored interventions for diverse patient populations.

Introduction

The advent of single-cell technologies has catalyzed a paradigm shift in cardiovascular medicine. Unlike conventional bulk tissue analyses, single-cell mapping elucidates the intricate cellular landscape of the heart, uncovering rare and functionally distinct cell populations previously masked by tissue-level averaging. This granular resolution informs disease mechanisms, patient-specific phenotypes, and therapeutic responsiveness, fostering precision cardiology. As cardiovascular diseases (CVD) remain the leading cause of global mortality, integrating single-cell insights into clinical practice holds substantial promise for improving outcomes through individualized care.

Epidemiology / Disease Burden

Cardiovascular diseases account for an estimated 17.9 million deaths annually worldwide, with ischemic heart disease and heart failure representing major contributors to morbidity and healthcare expenditure. The heterogeneity in disease presentation and progression, shaped by genetic, environmental, and cellular factors, complicates risk prediction and management. Conventional risk stratification tools inadequately account for inter-individual variability in cellular and molecular drivers of CVD. Single-cell mapping offers the potential to redefine disease subtypes and uncover novel risk markers, thereby addressing unmet epidemiological challenges.

Pathophysiology

The heart comprises diverse cell types, including cardiomyocytes, fibroblasts, endothelial cells, immune cells, and specialized conduction system components. Pathological stimuli such as ischemia, hypertension, and metabolic stress induce distinct cellular responses, contributing to maladaptive remodeling, fibrosis, and arrhythmogenesis. Single-cell transcriptomic and epigenomic profiling reveals differential gene expression, signaling networks, and cell-state transitions underpinning disease processes. For example, single-cell RNA sequencing (scRNA-seq) has identified subpopulations of activated fibroblasts driving fibrotic remodeling post-myocardial infarction and pro-inflammatory immune cell subsets implicated in myocarditis, providing mechanistic targets for intervention.

Risk Factors

Traditional risk factors for CVD hypertension, diabetes, dyslipidemia, smoking, and family history are well established. However, single-cell analyses have uncovered cellular correlates of these risk factors, such as endothelial dysfunction, vascular inflammation, and altered immune cell phenotypes, which may precede clinical manifestations. For instance, scRNA-seq studies in hypertensive patients have demonstrated increased pro-inflammatory macrophage infiltration and endothelial-to-mesenchymal transition, linking cellular phenotypes to systemic risk profiles. This mechanistic understanding enhances risk stratification and highlights novel biomarkers for early detection.

Clinical Features

Clinical presentations of cardiac diseases vary widely, encompassing asymptomatic structural changes, arrhythmic events, heart failure symptoms, and acute coronary syndromes. Single-cell mapping aids in correlating cellular alterations with phenotypic heterogeneity. For example, heart failure with preserved ejection fraction (HFpEF) exhibits distinct single-cell signatures in myocardial fibroblasts and endothelial cells compared to heart failure with reduced ejection fraction (HFrEF). Such differentiation facilitates more tailored clinical assessment and management strategies, enabling precise delineation of disease subtypes and their prognostic implications.

Diagnosis

Accurate diagnosis of cardiac diseases often relies on imaging, biomarkers, and functional assessments. Single-cell mapping augments diagnostic precision by enabling the identification of disease-specific cellular signatures and rare pathogenic cell populations. Liquid biopsy approaches, integrating circulating single-cell transcriptomic data, are emerging as minimally invasive diagnostic tools. For instance, the detection of circulating pro-fibrotic fibroblast or pro-inflammatory immune cell subsets may serve as early biomarkers of myocardial injury or ongoing inflammation, complementing traditional diagnostic modalities and enhancing sensitivity for subclinical disease.

Treatment & Management

Current therapeutic approaches to CVD are largely based on population-level evidence, with limited personalization. Single-cell mapping facilitates individualized therapy by identifying actionable cellular targets and predicting therapeutic response based on cellular phenotype. For example, anti-fibrotic agents may be selectively deployed in patients with a predominance of activated fibroblast subpopulations, while immunomodulatory therapies may benefit those with specific pro-inflammatory immune cell signatures. This approach optimizes treatment efficacy, minimizes adverse effects, and supports dynamic adjustment of therapy as cellular phenotypes evolve.

Recent Advances / Emerging Therapies

Recent advances in single-cell genomics and multi-omics integration have propelled the discovery of novel therapeutic targets and personalized interventions. CRISPR-based gene editing and RNA-targeted therapies are being developed to modulate disease-driving cell populations identified through single-cell analysis. Moreover, artificial intelligence and machine learning algorithms are increasingly employed to interpret complex single-cell datasets, enabling predictive modeling of disease progression and therapeutic outcomes. Early-phase clinical trials are evaluating cell-type-specific drugs and biologics, marking the dawn of precision pharmacotherapy in cardiology.

Guideline Recommendations

While formal guidelines incorporating single-cell mapping are in early stages, leading cardiology societies acknowledge the growing importance of precision medicine approaches. Consensus statements recommend the integration of advanced molecular profiling, including single-cell technologies, in research protocols and prospective registries. Ongoing guideline revisions are anticipated to incorporate validated single-cell-derived biomarkers and stratification tools, promoting evidence-based adoption in routine clinical practice as additional data emerge.

Conclusion

Single-cell cardiovascular mapping heralds a transformative era in cardiac care, enabling unprecedented insights into disease mechanisms, risk stratification, and personalized therapy. By bridging the gap between molecular discovery and clinical translation, this approach holds the potential to redefine diagnostic algorithms, therapeutic strategies, and prognostic paradigms in cardiology. Continued research, interdisciplinary collaboration, and guideline evolution will be pivotal in realizing the full clinical impact of single-cell technologies for tailored cardiovascular care.